DYNAVAX ANNOUNCES RESULTS OF HBV VACCINE STUDY

Dynavax Technologies has reported that a mid-stage trial of its hepatitis B virus (HBV) vaccine was successful, warranting further testing. The drug, Heplisav, fared well in a comparative test versus GlaxoSmithKline's Engerix-B vaccine.

The trial's focus was on patients with chronic renal failure who are about to or are already undergoing hemodialysis and are at "substantial risk" for an HBV infection, as well as those who are HIV positive or have hepatitis C infection for whom a co-infection with HBV is a serious possibility.